Biolojic Design Receives U.S. FDA Clearance of Investigational New Drug (IND) Application for BD200, the First Multibody to Enter Clinical Trials

On November 12, 2026 Biolojic Design, a biotechnology company that uses AI to create antibodies that act as programmable, intelligent therapeutic candidates, reported that the U.S. FDA has cleared the Investigational New Drug (IND) application for BD200, a multibody drug conjugate that targets both Trop2 and Nectin-4. The IND clearance enables initiation of Biolojic’s planned global Phase 1 clinical study in the United States focusing on patients with select solid tumors known to express Trop2 and Nectin-4.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The FDA’s clearance of our IND for BD200 is a significant step toward advancing the first multibody into clinical testing," said Yanay Ofran, Ph.D., CEO and founder of Biolojic Design. "In addition to marking an important milestone in the evolution of multi-specific antibodies, it is also an important achievement in the application of AI to drug design by showing that AI can support the creation of antibodies with unique properties and potentially transformative capabilities. We look forward to starting our Phase 1 study in the coming weeks."

"As we look to improve cancer treatment, the heterogeneity of tumor antigen expression and the development of resistance are significant challenges," said Roger Waltzman, M.D., Chief Medical Officer of Biolojic Design "As a multibody, BD200 has been designed to help overcome these hurdles with a flexible binding profile and a unique linker-payload profile that enables it to adapt to an individual patient’s tumor expression, potentially improving efficacy and safety."

Multibodies are standard-format, multi-specific antibodies in which each arm can alternatively bind to one or both of two targets. Targeting the validated oncology antigens Nectin-4 and Trop2, both of which may be expressed by a cancer cell, each arm of BD200 can individually bind to either antigen, with the goal of overcoming target expression heterogeneity and enabling BD200 to address a patient’s specific tumor antigen expression profile.

The BD200 Phase 1 Clinical Study

The Phase 1 clinical study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of BD200 in patients with tumors known to express these antigens. The study will be conducted in the U.S and globally. Once optimal biologic doses have been selected, the study will focus on one or more appropriate tumor types as well as potential monotherapy and combination therapy development pathways.

About BD200

BD200 is a multibody drug conjugate carrying a potent topoisomerase inhibitor payload that targets Trop2 and Nectin-4, two antigens that are expressed in a variety of solid tumors. As a multibody, BD200 can bind to Nectin-4 with both arms, Trop2 with both arms, or Trop2 with one arm and Nectin-4 with a second arm. In preclinical studies, BD200 was able to bind to both of these targets and adapt its specificity to the heterogeneous antigen expression on tumor cells, increasing efficacy and overcoming resistance when compared to standard monospecific antibody drug conjugates (ADCs) or a template bispecific ADC.

(Press release, Biolojic Design, NOV 12, 2026, View Source [SID1234674724])

Erasca Reports Third Quarter 2026 Business Updates and Financial Results

On November 12, 2026 Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, reported business updates and announced financial results for the fiscal quarter ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The emerging clinical profile of ERAS-0015 continues to support its potential as a foundational therapy across RAS-mutant cancers, both as a monotherapy and backbone for combination regimens," said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. "We are rapidly advancing toward three potentially registration-enabling trials in pancreatic and lung cancers. We are pleased that ERAS-0015 received Fast Track Designation for metastatic pancreatic cancer, which offers an opportunity for closer engagement with the FDA as we progress the program. With a strengthened balance sheet and experienced R&D leadership, we believe that we are positioned to execute our near-term milestones and advance programs addressing high unmet needs for patients with RAS-mutant cancers."

Research and Development (R&D) Highlights

•
FDA Fast Track Designation for ERAS-0015: In August 2026, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation (FTD) to ERAS-0015 for the treatment of patients with metastatic pancreatic adenocarcinoma. The designation is intended to facilitate development and expedite review of therapies for serious conditions with unmet medical needs and provides opportunities for more frequent FDA interactions as Erasca advances its planned Phase 3 trial in pancreatic cancer.
•
Presentations at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) (ENA) Symposium: In September 2026, Erasca announced two presentations at the ENA Symposium, taking place November 18–20, 2026, in Barcelona, Spain. An oral plenary presentation will feature updated ERAS-0015 monotherapy data from the ongoing AURORAS-1 Phase 1 trial, including additional patients and longer follow-up. A poster presentation will feature nonclinical data for the combination of ERAS-0015 and ERAS-4001 targeting active and inactive KRAS, including synergy in KRAS G12X-driven models.

Corporate Highlights

•
Strengthened R&D Leadership: In August 2026, Erasca appointed Charles Fuchs, M.D., M.P.H., as president of research and development, and David Chonzi, M.D., as senior vice president of global pharmacovigilance, both of whom joined Erasca’s leadership team.

•
Completed Upsized Financing: In July 2026, Erasca completed a successful upsized public offering, raising approximately $632.5 million in gross proceeds.

Key Upcoming Milestones

AURORAS-1 to -3: Trials for ERAS-0015 (potential best-in-class pan-RAS molecular glue)

•
Phase 1 monotherapy expansion data expected in the first half of 2027
•
Phase 1 combination dose escalation data, including panitumumab combination, expected in the first half of 2027
•
Potentially registration-enabling trial in second line or greater NSCLC expected to initiate in the first half of 2027
•
Phase 3 pivotal trial in first line PDAC expected to initiate in 2027
•
Phase 3 pivotal trial in RASm NSCLC expected to initiate in the second half of 2027 to the first half of 2028

BOREALIS-1: Phase 1 trial for ERAS-4001 (potential first-in-class pan-KRAS inhibitor)

•
Preliminary safety, tolerability, pharmacokinetics, and initial efficacy Phase 1 monotherapy data expected in the second half of 2026
•
Initiation of monotherapy expansion cohorts and combination dose escalation cohorts planned for 2027

Third Quarter 2026 Financial Results

Cash Position: Cash, cash equivalents, and marketable securities were $947.8 million as of September 30, 2026, compared to $341.8 million as of December 31, 2025. Erasca expects its current cash, cash equivalents, and marketable securities will be sufficient to fund the Key Upcoming Milestones set forth above in this press release.

Research and Development (R&D) Expenses: R&D expenses were $47.2 million for the quarter ended September 30, 2026, compared to $22.5 million for the quarter ended September 30, 2025. The increase was primarily driven by increases in expenses incurred in connection with clinical trials, preclinical studies, discovery activities, personnel costs, including stock-based compensation expense, outsourced services, and consulting fees.

General and Administrative (G&A) Expenses: G&A expenses were $12.3 million for the quarter ended September 30, 2026, compared to $10.1 million for the quarter ended September 30, 2025. The increase was primarily driven by personnel costs, including stock-based compensation expense.

Net Loss: Net loss was $51.3 million, or $(0.15) per basic and diluted share, for the quarter ended September 30, 2026, compared to $30.6 million, or $(0.11) per basic and diluted share, for the quarter ended September 30, 2025.

(Press release, Erasca, NOV 12, 2026, View Source [SID1234674673])

Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results

On November 12, 2026 Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, reported financial results for the third quarter ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Verrica made progress in growing our commercial YCANTH business for molluscum contagiosum while advancing our late-stage pipeline for two of the most prevalent skin diseases, and extending our cash runway during the third quarter," said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. "YCANTH had another record quarter for revenue, and we are now turning our focus to maximize conversion of written to filled prescriptions and ensuring optimal insurance coverage. The efforts that began earlier this year, most notably under our YCanthRx non-dispensing pharmacy option, have matured, and during the quarter we began realizing the benefits of these efforts with improvement in gross to net."

Dr. Rieger continued, "We are also executing on our label expansion strategy for YCANTH into common warts. In August, we announced the completion of enrollment in the first pivotal trial of our global Phase 3 program in common warts after an interim analysis recommended that no additional patients were needed to power the trial. We have also enrolled more than 50% of the current patient target in the second pivotal trial, and we expect topline data from these trials in the first quarter of 2027 and mid-2027, respectively. Under our current operating plan, including finishing the global Phase 3 program in common warts, and the full utilization of our credit facility, we now have sufficient liquidity to fund operations through data readouts for both pivotal trials of the common warts program. With a prevalence of approximately 22 million patients in the U.S. alone and no FDA-approved prescription drug therapies, we believe that securing a label expansion for YCANTH into common warts could represent a multibillion-dollar commercial opportunity, if approved. Finally, we are now exploring the potential of VP-315 to treat patients with Gorlin syndrome, a rare disease that leads to dozens or hundreds of basal cell carcinomas over the patient’s lifetime, often presenting them with substantial surgical fatigue. We believe our foundational data in sporadic BCC provides promise for the potential benefit of VP-315 to Gorlin patients, and we will provide more details as the clinical protocol and anticipated timelines are finalized. We are excited about our future at Verrica, having built a solid commercial foundation to support promotion of YCANTH for molluscum which we can leverage upon any approval of YCANTH for common warts or VP-315 for BCC or Gorlin syndrome."

Conference Call and Webcast Information

The Company will host a conference call on Thursday, November 12, 2026, at 4:30 pm ET, to discuss its third quarter 2026 financial results and provide a business update. To participate in the conference call, please use the following information:

Domestic Dial-In Number: Toll-Free: 1-833-419-0865

International Dial-In Number: 1-785-838-9333

Conference ID: VERRICA

Webcast: View Source;tp_key=5f6b4ae4b1

The call will be broadcast live over the web and can also be accessed on Verrica’s website: www.verrica.com. A replay will be available for one month in the Events Calendar of the Investors section of the Company’s website.

Business Highlights and Recent Developments

YCANTH (VP-102)

•
During the third quarter, the Company recorded YCANTH net product revenue of $5.7 million, up 11.9% over the previous quarter and 57.9% year-over-year, and total revenue of $6.9 million.

•
During the third quarter, YCANTH dispensed applicator units totaled 19,135, representing a year-over-year increase of approximately 36% from the third quarter of 2025. On a sequential basis, YCANTH dispensed applicator units decreased approximately 2.5% from the prior quarter. We believe this decrease reflects summer travel seasonality, with both patients and providers.

•
On September 30, 2026, the Company announced new pooled analysis data from its two registrational Phase 3 trials of YCANTH for molluscum. These data indicated that patients treated with YCANTH achieved complete clearance at a rate approximately four times faster than patients who were treated with a placebo, and three times as many YCANTH-treated patients achieved complete clearance at each treatment visit.

•
On August 27, 2026, the Company announced completion of enrollment in the first pivotal Phase 3 trial (COVE-2) studying YCANTH for the treatment of common warts and greater than 50% enrollment in the second pivotal Phase 3 trial (COVE-3). Topline data readouts for the trials are expected in the first quarter of 2027 and mid-2027, respectively.

•
On July 21, 2026, the Company announced an exclusive distribution, marketing and supply agreement with Medomie Pharma Ltd. regarding commercial rights for YCANTH for the treatment of molluscum contagiosum in Israel. The Company is working with Medomie to support their regulatory filing in Israel.

VP-315

•
On September 10 and 30, 2026, the Company announced encore poster presentations at various scientific meetings.

•
The Company is now exploring VP-315 for the treatment of patients with Gorlin syndrome, leveraging the extensive data from the completed Phase 2 study in sporadic BCC to this patient population with high disease burden and surgical fatigue, with no current FDA-approved products available for this indication. The Company is evaluating the potential study design and associated trial budget, and will update its business plan upon finalizing any study of VP-315 for the treatment of Gorlin syndrome

Corporate

•
On October 22, 2026, the Company announced achievement of milestones unlocking access to the remaining $15.0 million of non-dilutive growth capital under its $27.5 million credit facility with an entity controlled by Paul B. Manning, the Company’s Chairman and largest shareholder. With this additional borrowing capacity, based on the Company’s current business plan, the Company believes that its cash runway will extend into the fourth quarter of 2027, without giving effect to any potential clinical trial costs related to the study of VP-315 for the treatment of Gorlin syndrome.

Financial Results

Third Quarter 2026 Financial Results

•
Total revenue for the three months ended September 30, 2026, was $6.9 million compared to total revenue of $14.3 million for the three months ended September 30, 2025, which included a $10.0 million one-time milestone payment from Torii Pharmaceutical Co., Ltd., Verrica’s Japanese development partner.

•
U.S. YCANTH product revenue, net was $5.7 million for the quarter ended September 30, 2026, compared to net product revenue of $3.6 million for the quarter ended September 30, 2025. The increase in product revenue, net, was primarily related to increased deliveries of YCANTH to our distribution partners as well as improved yield from reduced spending on our co-pay assistance program.

•
License and collaboration revenue was $1.2 million for the quarter ended September 30, 2026, consisting primarily of commercial supply for Torii’s YCANTH launch in Japan, compared to license and collaboration revenue from Torii of $10.7 million for the three months ended September 30, 2025, which included $10.0 million of one-time milestone revenue, as well as $0.7 million of collaboration revenue for supplies and development activity with Torii.

•
Costs of product revenue were $0.6 million for the quarter ended September 30, 2026, compared to $0.8 million for the quarter ended September 30, 2025, consisting primarily of product costs related to the sale of YCANTH.

•
Selling, general and administrative expenses were $10.4 million for the quarter ended September 30, 2026, compared to $9.4 million for the same period in 2025. Excluding the impact of stock-based compensation, expenses were comparable to the prior period.

•
Research and development expenses were $7.6 million for the quarter ended September 30, 2026, compared to $2.2 million for the same period in 2025. Excluding the impact of stock-based compensation, the increase of $5.2 million was primarily attributable to an increase of $3.7 million in non-cash costs associated with the Phase 3 program for common warts, in addition to an increase of $1.3 million in expenses related to chemistry, manufacturing and controls across YCANTH and VP-315. The expense for the Phase 3 common warts program did not impact Verrica’s cash balance, as the first $40 million of payments for this program, representing approximately 90% of the current estimated study costs, will be made by Torii under the Company’s collaboration and license agreement.

•
Interest income was $45,000 for the quarter ended September 30, 2026, compared to $0.2 million for the quarter ended September 30, 2025. The decrease in interest income was primarily due to lower cash balances.

•
Interest expense was $0.3 million for the quarter ended September 30, 2026, compared to $2.1 million for the same period in 2025. The decrease of $1.8 million was related to the settlement and termination of the Company’s OrbiMed debt facility in November 2025, partially offset by imputed interest on the R&D funding liability and $0.1 million of interest expense on term loans borrowed under the Company’s new credit facility with an affiliate of Paul B. Manning, the Company’s Chairman and largest shareholder

•
For the quarter ended September 30, 2026, net loss was $12.4 million, or $0.58 per share, compared to a net loss of $0.3 million, or $0.03 per share, for the same period in 2025.

•
For the quarter ended September 30, 2026, non-GAAP net loss was $10.5 million, or $0.49 per share, compared to a non-GAAP net income of $1.1 million, or $0.12 per share, for the same period in 2025.

(Press release, Verrica Pharmaceuticals, NOV 12, 2026, View Source [SID1234674689])

Recordati and Partners to Present New Evidence and Guidance in Rare Hematologic Diseases at American Society of Hematology (ASH) Annual Meeting and Exposition

On November 12, 2026 Recordati Rare Diseases Inc. reported new data presentations across its rare hematology portfolio at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, December 12-15, 2026, in New Orleans, La. Recordati researchers and independent investigators will present findings from five studies spanning clinical research, diagnostic and disease management tools for cold agglutinin disease (CAD) and idiopathic multicentric Castleman disease (iMCD). Two additional iMCD abstracts are published in the November online supplement of Blood, the peer-reviewed journal of ASH (Free ASH Whitepaper).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Highlights include poster presentations on CAD, a rare type of autoimmune hemolytic anemia (AIHA), including international expert consensus treatment guidelines, a post-hoc analysis of the pivotal Phase 3 sutimlimab CARDINAL and CADENZA trials in CAD, and new real-world data from the CADENCE registry. These supplement guidance for patient care, and existing evidence extending beyond the duration of clinical trials of long-term sutimlimab safety and efficacy in CAD.

In iMCD research, there will be an oral presentation on an internationally validated patient-reported outcomes scale to assess disease symptom burden over time. Additional studies explore tools to support diagnostic accuracy and consistency of iMCD, including global use of an expert-curated, disease-specific digital pathology platform. Multicentric Castleman disease commonly presents with enlarged lymph nodes in multiple regions of the body and is often misdiagnosed because it mimics other diseases.

"We are excited about the progress that will be discussed at this meeting around the diagnosis and treatment of CAD and iMCD," said Milan Zdravkovic, Executive Vice President, Research & Development and Chief Medical Officer at Recordati. "This also includes data around the long-term management of these diseases. Through collaborations with researchers worldwide, we aim to continually advance care for patients living with these conditions."

"Recordati is proud to continue our support of the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting as we share research that reflects our commitment to patients with rare hematology and oncology disorders," said Melissa Koomey, President and General Manager of Recordati Rare Diseases North America. "We look forward to continuing our dialogue with the hematology/oncology community when we gather in December."

The ASH (Free ASH Whitepaper) 2026 Annual Meeting will feature the following presentations from Recordati and external investigators:

Cold Agglutinin Disease (CAD)

Title: Multinational Expert Delphi Consensus on Diagnosis and Treatment of Cold Agglutinin Disease*
Poster number: 4633
Presenting author: Ilene C. Weitz, MD, Keck School of Medicine, University of Southern California, Los Angeles

Title: Impact of delayed dosing on hemolytic markers and complement pathway activity in the phase 3 CARDINAL and CADENZA studies of sutimlimab in cold agglutinin disease: a post-hoc analysis
Poster number: 2875
Presenting author: Alexander Röth, MD, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen

Title: Baseline characteristics of cold agglutinin disease/cold agglutinin syndrome patients enrolled in the international CADENCE registry
Poster number: 1113
Presenting author: Catherine M. Broome, MD, Lombardi Cancer Center, MedStar Georgetown University

Title: Updated real-world outcomes of sutimlimab in patients with cold agglutinin disease/cold agglutinin syndrome from CADENCE: a multinational, multi-center, observational, prospective cohort study
Poster number: 4634
Presenting author: Alexander Röth, MD, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen

Castleman Disease

Title: Idiopathic multicentric Castleman disease (iMCD) symptom burden scale (ISBUS): International development and validation of a first-ever tool for assessing symptom burden in iMCD
Oral presentation number: 462
Presenting author: Sudipto Mukherjee, MD, PhD, MPH, Cleveland Clinic Cancer Institute
Presentation date & location: Saturday, December 12, 5:15 PM CT; Room: MCCNO – 260-262

Title: Scaling rare-disease pathology expertise: Real-world adoption of a whole-slide imaging and histologic grading platform for Castleman disease
Abstract book publication: 8612
Primary author: Robert S. Ohgami, MD, PhD, University of Utah, and ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine in Salt Lake City

Title: Divergent outcomes following treatment pauses in idiopathic multicentric Castleman disease: A registry-based case series
Abstract book publication: 6559
Primary author: Joshua Brandstadter, MD, PhD, Hospital of the University of Pennsylvania

*Triducive Partners Ltd. independently provided facilitation of the Delphi process and medical writing support. Funding was provided by Recordati Rare Disease Inc.

About Cold Agglutinin Disease (CAD)
Cold agglutinin disease (CAD) is a rare type of autoimmune hemolytic anemia (AIHA), characterized as a low-grade lymphoproliferative disorder of the bone marrow. In CAD, autoantibodies bind to erythrocytes at temperatures ≤37°C, leading to complement-mediated hemolysis. CAD symptoms include severe, debilitating fatigue and other clinical manifestations (e.g., dyspnea, tachycardia) that can impact patients’ quality of life. While the median age of onset is approximately 60 years, CAD has been diagnosed in patients as young as 30.

About Idiopathic Multicentric Castleman Disease (iMCD)
Idiopathic multicentric Castleman disease is a rare cytokine-driven disorder that may be life-threatening and can affect people of any age. Its symptoms often resemble those of malignant lymphoma, autoimmune, or infectious diseases, making it difficult to diagnose. iMCD is a subtype of Castleman disease (CD), which is a group of rare conditions that affect the immune system, characterized by swollen lymph nodes and a broad range of inflammatory signs and symptoms. The cause of iMCD is unknown, and there are no known risk factors. Some people with iMCD have elevated levels of interleukin 6 (IL-6), a cytokine that is produced in the body during inflammation and which plays a key pathological role in iMCD; IL-6 elevation may explain some of the symptoms patients experience, such as swollen lymph nodes, fever, unexplained weight loss, and night sweats.

INDICATION

ENJAYMO (sutimlimab-jome) is indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
ENJAYMO is contraindicated in patients with known hypersensitivity to sutimlimab-jome or any of the inactive ingredients.

WARNINGS AND PRECAUTIONS
Serious Infections Including Those Caused by Encapsulated Bacteria

ENJAYMO, a proximal classical complement C1s inhibitor, increases susceptibility to serious infections, including those caused by encapsulated bacteria e.g. Neisseria meningitidis (any serogroup, including non-groupable strains), Streptococcus pneumoniae, and Haemophilus influenzae type B.
Life-threatening and fatal infections with encapsulated bacteria have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors.
Serious infections (bacterial and viral) were reported in 15% (10/66) of patients receiving ENJAYMO in the two phase 3 trials. These infections included urinary tract infection with sepsis, respiratory tract infection, pneumonia, otomastoiditis, and skin infections. One patient (1.5%) died due to Klebsiella pneumoniae.
Complete or update vaccination against encapsulated bacteria at least 2 weeks prior to administration of the first dose of ENJAYMO, according to the most current ACIP recommendations for patients receiving a complement inhibitor.
If urgent ENJAYMO therapy is indicated in a patient who is not up to date on their vaccine(s), administer as soon as possible.
Vaccination does not eliminate the risk of serious encapsulated bacterial infections. Closely monitor patients for early signs and symptoms of serious infection and evaluate patients immediately if an infection is suspected.
If ENJAYMO treatment is administered to patients with active systemic infections, monitor closely for signs and symptoms of worsening infection. Some infections may become rapidly life-threatening or fatal if not recognized and treated promptly. Inform patients of these signs and symptoms and steps to be taken to seek immediate medical care.
Consider interruption of ENJAYMO treatment in patients who are undergoing treatment for serious infection.
Consider patients’ immune status when initiating treatment with ENJAYMO.
Infusion-Related Reactions

Administration of ENJAYMO may result in infusion-related reactions. In the two phase 3 trials, 29% (19/66) of patients treated with ENJAYMO experienced infusion-related reactions. One patient permanently discontinued ENJAYMO due to an infusion-related reaction.
Monitor patients for infusion-related reactions and interrupt if a reaction occurs.
Discontinue ENJAYMO infusion and institute appropriate supportive measures if signs of hypersensitivity reactions, such as cardiovascular instability or respiratory compromise, occur.
Risk of Autoimmune Disease

Based on its mechanism of action, ENJAYMO may potentially increase the risk for developing autoimmune diseases such as systemic lupus erythematosus (SLE). Development of SLE has been associated with inherited classical complement deficiency.
In clinical trials, 4.5% (3/66) of patients developed a relapse or worsening of previously diagnosed autoimmune disease.
Monitor ENJAYMO patients for signs and symptoms and manage medically.
Recurrent Hemolysis After ENJAYMO Discontinuation

If treatment with ENJAYMO is interrupted, closely monitor patients for signs and symptoms of recurrent hemolysis, eg, elevated levels of total bilirubin or lactate dehydrogenase (LDH) accompanied by a decrease in hemoglobin, or reappearance of symptoms such as fatigue, dyspnea, palpitations, or hemoglobinuria. Consider restarting ENJAYMO if signs and symptoms of hemolysis occur after discontinuation.
ADVERSE REACTIONS

The most common adverse reactions in the CADENZA trial (Part A) (incidence ≥18%) are rhinitis, headache, hypertension, acrocyanosis, and Raynaud’s phenomenon. The most common adverse reactions in the CARDINAL trial (incidence ≥25%) are urinary tract infection, respiratory tract infection, bacterial infection, dizziness, fatigue, peripheral edema, arthralgia, cough, hypertension, and nausea

(Press release, Recordati, NOV 12, 2026, View Source [SID1234674708])

Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates

On November 12, 2026 Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, reported third quarter 2026 financial results and provided updates on its programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The third quarter was marked by important progress across Eikon’s oncology programs," said Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon. "At the 2026 ESMO (Free ESMO Whitepaper) Congress, we presented updated results from TeLuRide-005, providing additional evidence of durable anti-tumor activity for EIK1001 in combination with standard-of-care therapy in squamous NSCLC, building on earlier data in non-squamous NSCLC that we shared at ASCO (Free ASCO Whitepaper). We also presented encouraging activity and tolerability data across our selective PARP1 inhibitor programs, supporting their continued development, alongside initial findings from our WRN inhibitor program. Taken together, these findings demonstrate the breadth of our clinical portfolio and reflect our broader mission at Eikon to translate rigorous science into innovative medicines with the potential to address important unmet needs in cancer therapy."

Clinical Development Highlights

EIK1001

EIK1001 is a systemically administered TLR 7/8 dual-agonist designed to stimulate both innate and adaptive immune responses to malignancy. Intravenous administration of EIK1001 has been observed to be generally well-tolerated, shown a pharmacodynamic profile consistent with systemic immune responses, and can be combined with current standard-of-care.

On October 26, 2026, Eikon presented updated data at the 2026 ESMO (Free ESMO Whitepaper) Congress from TeLuRide-005 (NCT06246110), an ongoing open-label Phase 2 trial evaluating the safety and tolerability of EIK1001 in combination with both pembrolizumab and histology-appropriate chemotherapy for the treatment of patients with NSCLC. Among other results, the presentation showed:
Across the pooled efficacy-evaluable population (n=65), EIK1001 in combination with pembrolizumab and chemotherapy resulted in an objective response rate (ORR) of 63.1% and disease control rate (DCR) of 89.2% at a median follow-up of 17.2 months, with objective responses observed across all PD-L1 tumor proportion score (TPS) subgroups.
In the squamous cohort, ORR was 72.4% and DCR was 100%, with a median duration of response (DOR) of 12.9 months at a median follow-up of 12.7 months.
In the non-squamous cohort, ORR was 55.6% and DCR was 80.6%, with a median DOR of 11.2 months at a median follow-up of 17.9 months.
The combination was generally well-tolerated, with an adverse event profile similar to standard-of-care alone and a tolerability profile supportive of systemic administration of EIK1001 in an outpatient setting.
On July 27, 2026, Eikon announced dosing of the first patient in TeLuRide-008 (NCT07365319), a Phase 2/3 registrational trial evaluating EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy as first-line therapy for treatment-naïve patients with stage 4 NSCLC. The trial is actively enrolling, with a prespecified interim analysis for dose selection anticipated in the second half of 2027.
EIK1003 & EIK1004

EIK1003 and EIK1004 are highly selective PARP1 inhibitors designed to inhibit PARP1 while sparing PARP2, thereby promoting tumor regression by targeting the DNA damage response of cancer cells. EIK1004 was specifically engineered to penetrate the central nervous system (CNS), potentially expanding the utility of selective PARP1 inhibition to tumors involving the brain. The selectivity of EIK1003 and EIK1004 may enable the development of near full-dose combination regimens with chemotherapy, antibody-drug conjugates, or radionuclides, in earlier lines of therapy than currently possible with non-selective PARP inhibitors, and potentially allow for more sustained therapeutic dosing during maintenance treatment.

On October 23, 2026, Eikon presented updated and initial clinical data at the 2026 ESMO (Free ESMO Whitepaper) Congress from its ongoing Phase 1/2 trial evaluating EIK1003 as a monotherapy and in combination with anti-cancer agents in participants with advanced solid tumors (NCT06253130). Among other results, the presentations showed:
In Cohort 1A, evaluating EIK1003 monotherapy, EIK1003 was generally well-tolerated across multiple dose levels. Among 49 efficacy-evaluable participants, the ORR was 14.3% overall and 31.3% among PARP inhibitor-naïve participants.
In Cohort 1B, evaluating EIK1003 in combination with abiraterone in patients with metastatic prostate cancer, the combination demonstrated a favorable tolerability profile and preliminary anti-tumor activity, including an ORR of 20.8% among 24 RECIST-evaluable participants and a prostate-specific antigen (PSA) response (greater than or equal to 50% from baseline) in 30.8% of PSA-evaluable participants.
In Cohort 1C, evaluating EIK1003 in combination with weekly paclitaxel in patients with ovarian or breast cancer that had failed appropriate therapy, signals of anti-tumor activity were observed, with an ORR of 26.4% among 53 efficacy-evaluable participants, including one confirmed complete response and 13 partial responses, and with 86% of responders having had prior taxane exposure.
On October 23, 2026, Eikon also presented initial clinical data at the 2026 ESMO (Free ESMO Whitepaper) Congress from its ongoing Phase 1/2 trial evaluating EIK1004 (NCT06907043). EIK1004 was generally well-tolerated, with minimal hematologic toxicity, across multiple dose levels. Among 58 efficacy-evaluable participants, ORR was 12.1% and DCR was 62.1%, with responses observed in breast, ovarian and prostate cancers.

EIK1005

EIK1005 is a novel molecular entity, designed to inhibit the Werner (WRN) helicase, that emerged from original research conducted in Eikon’s laboratories. EIK1005 has the potential to be an effective anti-tumor agent for microsatellite instability-high (MSI-high) tumors by producing synthetic lethality in MSI-high cells that depend upon the WRN helicase salvage pathway to maintain genome integrity.

On October 23, 2026, Eikon presented preliminary clinical data at the 2026 ESMO (Free ESMO Whitepaper) Congress from EIK1005-002, an ongoing Phase 1/2 trial evaluating EIK1005 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors (NCT07262619). Among other results, the presentation showed:
EIK1005 was generally well tolerated and demonstrated a pharmacokinetic profile supporting once-weekly administration.
6 of 8 efficacy-evaluable participants in the monotherapy dose-escalation portion achieved stable disease (SD), all of whom had confirmed DNA mismatch repair deficiency (dMMR) or MSI-high tumors.
The first participant enrolled in the combination dose-escalation portion with pembrolizumab achieved a partial response at the first post-baseline scan.
EIK1006

EIK1006 is an internally-derived clinical candidate and is being investigated as a potential next-generation androgen receptor (AR) antagonist with activity against wild type and multiple clinically important genetic variants of AR that emerge during treatment with conventional AR antagonists. Preclinically, Eikon scientists have shown that EIK1006 binds to the ligand binding domain of AR and blocks its nuclear translocation, thereby inhibiting AR transcriptional activity and downstream signaling.

On October 14, 2026, Eikon submitted an IND application to the U.S. Food and Drug Administration (FDA) to evaluate EIK1006 for the treatment of advanced metastatic prostate cancer.

Key Upcoming Milestones

EIK1001: Prespecified interim analysis for advancement to Phase 3 for TeLuRide-006, a registrational Phase 2/3 trial of EIK1001 in combination with pembrolizumab in advanced melanoma, is anticipated in the first half of 2027, and prespecified interim analysis for dose selection in the ongoing TeLuRide-008 Phase 2/3 trial of EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy as first-line treatment for patients with stage 4 NSCLC is anticipated in the second half of 2027.
EIK1003: Eikon expects initial results from Cohort 1D of the ongoing Phase 1/2 study evaluating EIK1003 in combination with paclitaxel and platinum-based chemotherapy in the second half of 2027, and expects to complete the ongoing Phase 2 dose-optimization portion of the EIK1003 trial in the second half of 2027.
EIK1004: Eikon plans to initiate a combination arm in the Phase 1/2 study to evaluate EIK1004 with docetaxel in patients with castrate-resistant prostate cancer and expects to report initial results from that combination arm in the second half of 2027.
EIK1005: Eikon expects additional results from the Phase 1/2 study evaluating EIK1005 in combination with pembrolizumab in the first half of 2027 and complete results from the EIK1005 monotherapy portion of the trial in the second half of 2027.
EIK1006: Subject to FDA clearance, Eikon plans to initiate a Phase 1/2 study in metastatic prostate cancer and anticipates preliminary safety and efficacy data to be available in the second half of 2027.

Third Quarter 2026 Corporate Highlights

Appointment of Ching-Pin (CP) Chang, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer

On September 3, 2026, Eikon appointed Ching-Pin "CP" Chang, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer. Dr. Chang is a physician-scientist with more than two decades of experience spanning academic medicine, fundamental research and drug discovery. He joined Eikon from Bristol Myers Squibb, where he most recently served as Vice President, Head of Cardiovascular Discovery Biology and Translational Pharmacology. Previously, he served in research leadership roles at Gilead Sciences, at MyoKardia and held academic positions at Stanford University and at the Indiana University School of Medicine.

Third Quarter 2026 Financial Results

Cash Position: As of September 30, 2026, Eikon had cash, cash equivalents, and marketable securities of $461.7 million. Net cash used in operating activities was $224.0 million for the nine months ended September 30, 2026. Eikon expects its current cash, cash equivalents, and marketable securities to fund operations into the first quarter of 2028.

Research and Development (R&D) Expenses: R&D expenses were $71.8 million for the three months ended September 30, 2026 compared to $59.3 million for the three months ended September 30, 2025, an increase of $12.5 million, or 21%. Direct research and development expenses increased $9.2 million as we advanced our clinical trial activity, and compensation costs increased $3.0 million.

General and Administrative (G&A) Expenses: G&A expenses were $18.7 million for the three months ended September 30, 2026, compared to $15.4 million for the three months ended September 30, 2025, an increase of $3.3 million, or 21%. This increase was primarily due to $1.5 million higher professional fees from consulting and legal expenses and $1.1 million higher other operating expenses, primarily IT expenses.

Net Loss: Net loss attributable to common stockholders was $86.1 million for the third quarter of 2026, as compared to $71.1 million for the prior-year period.

"We ended the third quarter with $461.7 million in cash and are updating our runway guidance into the first quarter of 2028, through the key clinical milestones anticipated in 2027," said Freddie Bowie, Ph.D., Chief Financial Officer. "We have remained focused on disciplined capital allocation. Operating expenses for the nine months ended September 30, 2026 increased 6% year over year, with G&A down 24% and R&D representing 80% of the total. We are concentrating investment behind our most advanced programs and tying incremental spending to clinical milestones, with the goal of creating long-term shareholder value."

(Press release, Eikon Therapeutics, NOV 12, 2026, View Source [SID1234674725])